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Abstract Protein kinase CK2, a ubiquitous serine/threo-
nine kinase in control of a variety of crucial cellular
functions, is composed of catalytic a- and a0-subunits and
non-catalytic b-subunits which form holoenzymes such as
CK2(ab)2, CK2aa0b2, or CK2(a0b)2. In addition, there is
ample evidence for the occurrence of the individual sub-
units beside the holoenzyme. While the CK2 subunits are
well analyzed on the protein level, only little is known
about the regulation of their transcription. The existence of
multiple forms of CK2 subunits raised the question about a
mutual regulation of their expression. Here we defined two
50-upstream regions of the CK2a and the CK2b genes,
respectively, as sequences with promoter activities. We
found that CK2a and CK2a0 stimulated the expression of
the reporter constructs whereas, CK2b was inactive. Using
chromatin immunoprecipitation assays, we were unable to
detect binding of endogenous CK2 subunits to these pro-
moter sequences in vivo. However, it turned out that
inhibition of the kinase activity of CK2 attenuated the
promoter activity indicating that CK2a and CK2a0 might
regulate their gene expression indirectly by phosphoryla-
tion reactions. Thus, we have shown here (i) that under
normal physiological conditions CK2 does not bind to CK2
promoter regions and (ii) that the CK2 kinase activity is
implicated in the regulation of its own expression.
Keywords Protein kinase CK2  Gene expression 
Transcriptional regulation  DNA binding
Introduction
Protein kinase CK2, formerly known as casein kinase 2, is
known for more than 50 years [1]. It is a ubiquitously
expressed protein kinase which phosphorylates more than
500 different substrates and this number is steadily
increasing. This large number of different substrates indi-
cates that CK2 is implicated in numerous cellular processes
including regulation of cell proliferation and survival [2,
3]. An elevated expression level and an increased kinase
activity for CK2 were found in tumor cells compared to
normal, non-transformed cells [4]. This later observation
made CK2 an interesting pharmacological target for the
treatment of cancer [5, 6].
Thornburg and Lindell [7] first described CK2 as a
multi-subunit protein kinase that is generated by the asso-
ciation of two a- and/or a0-subunits with a dimer of the
b-subunit. This structure and composition of CK2 was
quickly confirmed by Dahmus and Natzle [8]. Stigare,
however reported in 1993, that CK2a was tightly bound to
nuclear structures in the absence of its b-subunit [9] indi-
cating that the CK2 subunits exist not only in the holoen-
zyme but also in a free form or individually associated with
other cellular proteins or structures. An unbalanced
expression of CK2a and CK2b subunits was later on
described for different mammalian tissues [10–12]. CK2a
is not only active as a phosphotransferase in the holoen-
zyme but also in the absence of CK2b. Loss of CK2b is
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lethal [13] which may imply that some aspects of the CK2b
functions are not based on its interaction with the CK2a
subunits. Live cell fluorescence imaging revealed that
CK2a and CK2b show an independent movement within a
eukaryotic cell. Furthermore, CK2a and CK2b enter the
nucleus independently [14]. Unlike CK2b, nuclear CK2a
can be exported back to the cytosol. Finally, a large excess
of CK2b is synthesized compared to CK2a and the non-
complexed CK2b protein is rapidly degraded [15]. The
human genome contains two CK2a loci, at chromosomes
20p13 and 11p15, where primarily the locus on chromo-
some 20 is transcriptionally active. The locus on chromo-
some 11 was thought to be a permanently silent
pseudogene [16–19]. However, it turned out that this in-
tronless CK2a gene is expressed in some cancer cells but
only minimally expressed in normal cells [20]. It therefore
still has to be clarified whether or not it is a protein-coding
gene or a processed pseudogene.
The CK2a0 gene has been mapped to chromosome
16p13.2–13.3 [21], whereas the CK2b gene has been
mapped to chromosome 6p21.3 [17]. The genomic struc-
tures of the different CK2 genes in various organisms have
been characterized [22–28]. Due to the fact that the indi-
vidual CK2 subunits assemble into the holoenzyme, which
is composed of two CK2a or CK2a0 and two CK2b sub-
units and that the subunits exist outside of the holoenzyme,
it was an obvious question whether the expression of the
subunits might be coordinately regulated. The promoter
regions for the different CK2 genes were characterized and
furthermore it was shown, that CK2a appears to function as
a trans-activating factor for the CK2b gene transcription
[29]. Electrophoretic Mobility Shift Assays (EMSA) sug-
gested a binding of CK2a to the CK2b promoter. Over-
expression of CK2a resulted in an elevated level of CK2b
protein which might suggest that CK2a stimulate the
transcription of CK2b although other mechanisms are
possible. Previously, it has been shown that CK2 activity is
down-regulated at the transcriptional level in both senes-
cent lung fibroblasts and in aged rat tissues and it has been
proposed that DNA methylation may be involved in inac-
tivating CK2 in senescent cells [30]. Possibly, promoter
methylation may be used as a general mechanism for
regulation of CK2 expression. However, so far there is no
indication for direct methylation of the CK2a and CK2b
promoters [31].
While the cellular stoichiometry of the catalytic and the
regulatory subunits are well characterized, the situation at
the transcriptional level is less clear. Thus, we decided to
analyze the influence of CK2a, CK2a0, and CK2b on the
CK2a and CK2b promoters. In contrast to previous studies,
we used DNA sequences of at least 1.3 kb directly
upstream of the translational start sites instead of small
DNA fragments. We found that the CK2 catalytic subunits
stimulated the expression of both, the CK2a and CK2b
genes. However, using chromatin immunoprecipitation
assays, we found no direct binding of CK2a and CK2b to
these promoter DNAs. Instead, transcription was attenuated
after inhibition of the CK2 kinase activity by two different
CK2 inhibitors indicating that the enzyme activity is nec-
essary for transcriptional regulation of the CK2 subunits.
Materials and methods
Cell culture and drug treatment
HCT116 cells are human colon carcinoma cells, which
were previously characterized in detail [32] and were a
kind gift from Vogelstein [33]. Cells were cultured in
McCoy0s 5A Modified Medium with GlutaMAXTM-I (Life
Technologies, Darmstadt, Germany) containing 10 % fetal
calf serum (FCS; PAA, Pasching, Austria) at 37 C and
5 % CO2 in a humidified atmosphere. For selective inhi-
bition of endogenous CK2 kinase activity, HCT116 cells
were treated with CK2 inhibitors CX-4945 (1 or 10 lM in
DMSO, Selleckchem, Mu¨nchen, Germany) or TF (50 lM
in DMSO, a kind gift from Joachim Jose´ [34]) for 24 h or
with DMSO as solvent control.
CK2 protein kinase assay
To study CK2 kinase activity in cell extracts, 30 lg of total
protein was mixed with 20 ll of kinase buffer [50 mM Tris–
HCl, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 mM dithio-
threitol (DTT)]. After addition of 30 ll of CK2 assay mix
(25 mM Tris–HCl, pH 8.5, 150 mM NaCl, 5 mM MgCl2,
1 mM DTT, 50 lM ATP, 0.19 mM CK2-specific substrate
peptide with the sequence RRRDDDSDDD, 10 lCi
(0.37 MBq) [c-32P]ATP), the reaction mix was incubated at
37 C for 5 min and then stopped on ice. The sample was
pipetted onto Whatman-P81 cation-exchange paper and
washed three times with 85 mM phosphoric acid for 5 min,
followed by washing with ethanol. The dried filter paper was
counted for Cˇerenkov radiation in a scintillation counter
(Liquid Scintillation Analyzer 190S AB/LA; Canberra-
Packard GmbH, Dreieich, Germany).
Plasmids and cloning of promoter constructs
Firefly luciferase reporter vector (pGL4.10) and Renilla
luciferase reporter control vector (pGL4.70) were from
Promega (Mannheim, Germany). The human CK2a (PI)
promoter fragment, containing 1329 nucleotides upstream
of the start codon, was obtained by PCR amplification with
the primers CK2a-hum-prom-ATG-1329-for: 50-ATG
AAG CTT GTG CGG TGG CTC ACA TCT GTG-30;
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CK2a-hum-prom-ATG-rev: 50-ATG CCA TGG GCA TGT
CAG ACA GGT TGG CGG AC-30 and cloned (HindIII/
NcoI) into pGL4.10. The human CK2a (PII) promoter
fragment, containing 1920 nucleotides upstream of the first
exon, was obtained by PCR amplification with the primers
CK2a-hum-prom-up-for: 50-ATG AGA TCT AGG TAA
GCT CCA CCA GTG AGC-30; CK2a-hum-prom-up-rev:
50-ATG AAG CTT GCT CTC CCC TCT GCT CAC AC-30
and cloned (BglII/HindIII) into pGL4.10. The human CK2b
promoter fragment, containing 1896 nucleotides upstream
of the start codon, was obtained by PCR amplification with
the primers CK2b-hum-prom-for: 50-AGA AGA TCT
CGG GGA GAG TCT C-30; CK2b-hum-prom-rev: 50-ATG
CCA TGG AGC TGC TCA TCT TCA CGT CAG-30 and
cloned (BglII/NcoI) into pGL4.10. All sequences of cloned
fragments were confirmed by DNA sequencing.
The p3xFLAG-CMV-7.1-basic vector was from Sigma-
Aldrich (Mu¨nchen, Germany). To generate the expression
plasmids p3xFLAG-CMV-7.1-CK2a and p3xFLAG-CMV-
7.1-CK2a0, the human cDNA of CK2a (1176 nucleotides)
and CK2a0 (1050 nucleotides) were cloned into p3xFLAG-
CMV-7.1-basic with HindIII and BamHI. The sequences of
both DNA constructs were verified by sequencing. The
expression plasmids of the kinase-dead mutants CK2amut
(K68M) and CK2a0mut (K69M) were a generous gift from
Litchfield [35]. Both cDNAs were subcloned in p3xFLAG-
CMV-7.1-basic vector as described earlier [36]. The pro-
basin promoter construct was a kind gift from Thomas
Kietzmann and Elitsa Dimova.
Transient transfection, cell lysis, and luciferase assay
Transfection of cells was performed by using the Turbofect
Transfection Reagent (Thermo Scientific, St. Leon-Rot,
Germany) according to the manufacturer’s instructions.
For the luciferase reporter assay, HCT116 cells were
seeded into a 24-well plate (40,000 cells per well) in a total
volume of 0.5 ml/well of cell culture medium and cultured
overnight. Cells were then transfected using a total of 1 lg
of plasmid DNA by using Turbofect transfection reagent
(transfection mixture per well: 0.3 lg of promoter reporter
plasmid, 0.2 lg of Renilla luciferase control plasmid, 0.5 lg
of indicated expression plasmid, 2 ll Turbofect transfec-
tion reagent and 200 ll cell culture medium without FCS).
For western blot analysis, HCT116 cells were seeded into a
6-well plate (800,000 cells per well) in a total volume of 2 ml/
well of cell culture medium. Cells were cultured overnight
and were then transfected using Turbofect transfection
reagent using a total of 4 lg of plasmid DNA (transfection
mixture per well: 1 lg of promoter reporter plasmid, 1 lg of
Renilla luciferase control plasmid, 2 lg of indicated expres-
sion plasmid, 6 ll of Turbofect transfection reagent and
400 ll of cell culture medium without FCS).
For measuring luciferase activity, cells were collected at
given time points after transfection by lysing in passive
lysis buffer (PLB, Promega) and measured with the Dual-
Luciferase Reporter Assay System (Promega) following
the manufacturer’s recommendations. Relative light units
(RLUs) were calculated by normalizing firefly luciferase
activity to Renilla luciferase activity.
For western blot analysis, cell lysates were centrifuged
at 13,0009g to remove cell debris. The protein content was
determined with the Roti-Quant kit (Roth, Karlsruhe,
Germany). Protein extracts were immediately used for
western blot analysis or stored at -20 C.
SDS-polyacrylamide gel electrophoresis and western
blot analysis
Proteins were analyzed by SDS-polyacrylamide gel electro-
phoresis following standard protocols [37]. In brief, 50 lg of
proteins per lane were dissolved in sample buffer (130 mM
Tris–HCl, pH 6.8, 0.02 % bromophenol blue (w/v), 10 %
b-mercaptoethanol, 20 % glycerol (v/v), and 4 % SDS (w/v))
and separated on a 12.5 % SDS-polyacrylamide gel in elec-
trophoresis buffer (25 mM Tris–HCl, pH 8.8, 192 mM gly-
cine, and 3.5 mM SDS) and transferred onto a PVDF
membrane (Roche Diagnostics, Mannheim, Germany) in a
buffer containing 20 mM Tris–HCl, 150 mM glycine,
pH 8.3. The membrane was blocked with 5 % dry milk in
PBS with 0.1 % of Tween20 (PBST) for 1 h and then incu-
bated with appropriate primary antibodies diluted in PBST
with 1 % dry milk (incubation buffer). For the detection of
protein kinase CK2, we used rabbit anti-peptide serum #26
(a-subunit) [38], rabbit polyclonal anti-CK2b serum and the
monoclonal antibody anti-FLAGM2 (F3165, Sigma-
Aldrich). We used an a-tubulin-specific mouse monoclonal
antibody (clone DM1A, Sigma-Aldrich) as loading control.
All the antibodies were diluted 1:1,000 in incubation buffer
and incubated with the membrane for 1 h at room temperature
or overnight at 4 C. The membrane was washed twice with
incubation buffer and incubated with a horseradish peroxi-
dase (HRP)-conjugated secondary antibody (goat anti-rabbit
IgG, 1:30,000 or goat anti-mouse IgG 1:30,000 in incubation
buffer; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
1 h at room temperature. Chemiluminescence signals were
visualized by the ECL Lumilight system of Roche Diagnos-
tics according to the manufacturer’s instructions.
Chromatin immunoprecipitations (ChIP)
ChIP assays were performed with minor modifications as
described earlier [39]. 1 % of crosslinked and sonicated
chromatin of HCT116 cells was taken as input and kept at
4 C overnight instead of precipitation. DNA from approxi-
mately 2.5 9 106 cells was used in each immunoprecipitation
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with the following antibodies: anti-CK2a, rabbit anti-peptide
serum #26 [38]; anti-CK2b, rabbit polyclonal antibody
against full length protein; anti-SP1 rabbit polyclonal anti-
body (07–645, Merck Millipore, Darmstadt, Germany); nor-
mal rabbit IgG (sc-2027, Santa Cruz Biotechnology), used as
a control for non-specific signals. For the precipitations, 1 lg
of normal rabbit IgG, 4 lg of antibody anti-SP1, and 20 ll of
anti-peptide sera were utilized. After addition of the anti-
bodies, the samples were incubated at 4 C overnight on a
rotating wheel. Twenty-five microlitre of Protein G Dynabead
suspension (Life Technologies) were used to purify antibody-
bound protein–DNA complexes. The beads were washed
seven times with wash buffer (0.25 M LiCl, 0.5 % (v/v)
Nonidet P-40, 0.5 % (w/v) sodium deoxycholate, 1 mM
EDTA, 10 mM Tris–HCl, pH 8.0) before the bound com-
plexes were eluted twice, each with 100 ll elution buffer
(50 mM Tris–HCl, pH 8.0, 0.1 % (w/v) SDS, 10 mM
EDTA) at 28 C. After elution, formaldehyde crosslinks were
reversed and DNA was precipitated and purified. qPCR was
then carried out using the Brilliant III Ultra-Fast SYBR
Green QPCR Master Mix kit (Agilent Technologies, Bo¨b-
lingen, Germany) with the following primers (Fig. 1a, b):
ChIP-CK2a hum for: 50-GGG AGG TTC GTG TTC TCT
CT-30, ChIP-CK2a hum rev: 50-GGA ATC TCT CTG AAT
GCG GC-30; ChIP-CK2b hum for: 50-CCA TAA GGA CCC
AGC GGA TTG-30, ChIP-CK2b hum rev: 50-CAA CGA
GAA GCC ACC GGA AG-30, ChIP-GAPDHS hum for:
50-AGA CCA GCC TGA GCA AAA GA-30, ChIP-GAPDHS
hum rev: 50-CTA GGC TGG AGT GCA GTG GT-30. Product
amplification was carried out with an annealing temperature
of 62 C for 40 cycles using 1 ll of DNA solution as template
in the PCR Reader Mx3000ProTM (Agilent Technologies).
All PCR results were normalized to input controls.
Statistical analysis
Results of luciferase reporter assays in Fig. 2a, d were
expressed as mean ± standard deviation (SD) of at least
eight independent experiments. Statistical analysis of the
data was performed using the Two-sample t-test (Origin
software; OriginLab Corporation, Northampton, MA,
USA). p \ 0.05 was considered significant.
Results
The relevant promoter regions of CK2 subunit genes
reside upstream of their respective transcriptional start
sites
For the analysis of transcriptional regulation of CK2 sub-
unit expression, relevant promoter regions have to be
identified. Especially the organization of the CK2a gene
with the first untranslated exon located over 35 kb
upstream of its translational start site emerges the question,
which DNA region harbors the relevant promoter region of
this gene. Therefore, in contrast to previous studies [29],
we amplified extended DNA regions of over 1.3 kb directly
upstream of the CK2a start codon (PI, Fig. 1a) as well as
nearly 2 kb immediately upstream of the distant tran-
scriptional start sites of the CK2a gene (PII, Fig. 1a) by
PCR and cloned both potential CK2a promoter fragments
into luciferase reporter vector pGL4.10. For analysis of the
transcriptional regulation of the CK2b gene, we amplified
and cloned a DNA fragment encompassing 1.9 kb
upstream of the CK2b start codon, including the tran-
scriptional start site, the first untranslated exon 1 as well as
intron 2 of the CK2b gene (Fig. 1b).
HCT116 cells were transfected with the reporter con-
structs together with a Renilla luciferase plasmid to cal-
culate the transfection efficiency. As a further control, we
also transfected the vector DNA without the putative pro-
moter regions into HCT116 cells. Cells were extracted and
the luciferase activity was measured as described in
‘‘Materials and methods’’ section. The luciferase reporter
gene assays reveal clearly that only those DNA sequences
directly upstream of the transcriptional start site of CK2a
and CK2b genes, PII and CK2b, exhibit very strong pro-
moter activities (Fig. 1c). The sequence immediately
upstream of the translational start site (PI) showed no
promoter activity. Therefore, no further experiments were
carried out with this inactive reporter construct. For sim-
plicity, the active promoter construct CK2a (PII) is here-
inafter called CK2a promoter. In the next step, we analyzed
whether the reporter assay is dose dependent. Therefore,
50, 100, or 300 ng of the promoter constructs were trans-
fected into HCT116 cells. The following reporter assay
revealed that the luciferase activity increased with
increasing concentrations of the reporter constructs
(Fig. 1d). The relative luciferase light units were displayed
relative to the vector control.
Ectopic expression of catalytic CK2 subunits
but not of their kinase-dead mutants leads to a modest
but significant increase in promoter activity of CK2a
and CK2b promoters
Regulation of CK2a and CK2b gene expressions at the
transcriptional level is not well characterized to date. More
than 20 years ago CK2a was found to bind to calf thymus
DNA and to k-phage DNA [40]. Later on, the CK2a pro-
tein was found to complex with the CK2b gene promoter
[29]. Therefore, we decided to analyze whether the cata-
lytic subunits of CK2 (CK2a or CK2a0) might influence the
expression of CK2 subunits. To this end, we transiently
transfected cells with an active reporter construct
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(CK2a-luc and CK2b-luc, respectively), together with
plasmids coding for CK2a, CK2a0 or an empty vector
control. Our data clearly demonstrated a modest but sig-
nificant increase in CK2a as well as CK2b promoter
activities after ectopic expression of CK2a (Fig. 2a) and
CK2a0 subunits (Fig. 2d). These trans-activating effects
observed 24 h after transfection increased further when
incubation time was extended to 48 h. No further increase
was observed 72 h after transfection (Fig. 2a, d). Western
blot analysis with aliquots of transfected cells demon-
strated protein expression of FLAG-tagged CK2a and
CK2a0 subunits, respectively (Fig. 2a, d) demonstrating
that similar amounts of CK2a or CK2a0 were used for the
determination of the luciferase activity. In contrast, ectopic
expression of kinase-inactive mutants of CK2a(K68M) or
CK2a0(K69M) [35] significantly influenced neither CK2a
nor CK2b promoter activities (Fig. 2c, f), although
cotransfection of expression plasmids for these mutants
lead to a clear increase in the respective protein level
(Fig. 2c, f). As a further control, we analyzed effects of
ectopic expression of FLAG-tagged CK2a and CK2a0
subunits towards (i) the probasin promoter and (ii) the
empty reporter plasmid pGL4.10. We found that expression
of CK2a or CK2a0 had no influence, neither on the empty
reporter plasmid (pGL4.10) nor on the probasin promoter
(Fig. 2b, e).
As CK2a and CK2b form heterotetramers, we additionally
analyzed promoter activities after co-expression of both
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Fig. 1 Genomic architecture of CK2 genes and identification of
relevant promoter regions. Positions of transcription start sites, exons,
introns, start ATGs, and primers used for ChIP analyses (Fig. 4) are
shown. a Potential promoter regions (PI and PII) of CK2a gene are
enlarged and cloned DNA-fragments are depicted by black bars in
front of the coding sequence of the firefly luciferase gene (Luc).
Nucleotide positions relative to the original translational start site of
CK2a gene are indicated. b The potential promoter region of the
CK2b gene is enlarged and the cloned DNA-fragment is depicted by a
black bar in front of the coding sequence of the firefly luciferase gene
(Luc). Nucleotide positions relative to the original translational start
site of the CK2b gene are indicated. c, d Dual luciferase reporter gene
assays were carried out in HCT116 cells after transient transfection of
250 ng or indicated amount of different CK2 promoter constructs.
c Empty firefly luciferase reporter vector (pGL4.10) served as vector
control. Relative luciferase light units (RLU) were displayed relative
to the vector control. Mean ± SD, n = 3. d Relative luciferase light
units (RLU) of one representative experiment are shown
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CK2a/CK2a0 and CK2b subunits, alone and in combination.
As expected, ectopic expression of CK2b alone did not
change CK2 promoter activities significantly (Fig. 3a),
whereas CK2a and CK2a0 led to a moderate but significant
increase of both promoter activities (Fig. 3b, c). Surprisingly,
neither CK2a nor CK2b promoter activities increased further
after combined overexpression of CK2a and CK2b subunits
(Fig. 3b). Also combined expression of CK2a0 and CK2b
subunits, did not significantly change CK2a promoter activity
(Fig. 3c). Solely, the activity of the CK2b promoter seemed to
be slightly increased after combined CK2a0 and CK2b
expression. Taken together, these data indicate that obviously
monomeric CK2 rather than the holoenzyme is responsible
for the observed autoregulation of CK2 expression.
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Fig. 2 Ectopic expression of catalytic subunits of CK2 significantly
increases promoter activities of CK2a and CK2b promoters. Dual
luciferase reporter gene assays were carried out in HCT116 cells after
transient cotransfection of expression plasmids of wild-type CK2a
(a) or CK2a0 (d) or kinase-dead mutants of CK2a (c) or CK2a0
(f) together with indicated CK2 promoter constructs or an irrelevant
promoter construct (probasin promoter construct) or empty reporter
plasmid (pGL4.10) as negative controls (b, e). The empty expression
plasmid p3xFLAG-CMV-7.1 served as vector control in each case.
Relative promoter activities measured 24, 48, or 72 h after transient
transfection, are presented here. CK2 promoter activities measured
after cotransfection with the vector control were set to 100 %. Means
and standard deviations of eight independent experiments are shown.
*p \ 0.05; **p \ 0.01; ***p \ 0.001. Western blot analyses of
cotransfected HCT116 cells were analyzed in parallel and illustrate
expression of FLAG-tagged wild-type CK2a (a), FLAG-tagged
CK2amut (c), FLAG-tagged wild-type CK2a0 (d), or FLAG-tagged
CK2a0mut (f). Anti-FLAG antibody was used at a dilution of 1:1,000.
Detection of a-tubulin protein by anti-a-tubulin antibody, at a dilution
of 1:1,000, was used as a loading control for the extracts in the
experiments
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Transcriptional regulation of CK2 subunits expression
through CK2a and CK2b is not dependent on their
direct binding to promoter DNA
As expression of the CK2a subunit leads to an increase in
promoter activities of their respective genes, we wondered
whether the CK2a subunit might influence CK2a and
CK2b transcription through direct binding to their pro-
moter regions. To analyze direct binding of CK2 subunits
to the respective CK2 promoter regions in vivo, we per-
formed chromatin immunoprecipitation (ChIP) experi-
ments. It was previously shown that the general
transcription factor SP1 binds to a minimal fragment of the
CK2a promoter [41] as well as to the CK2b promoter [42].
Therefore, serving as a positive control in our ChIP assay,
endogenous SP1 was found to bind to CK2a as well as
CK2b promoter regions in vivo (Fig. 4). In contrast to SP1,
neither endogenous CK2a nor CK2b were able to bind
CK2a or CK2b promoter DNA in vivo (Fig. 4). As a
negative control, none of these proteins bind to the testis-
specific glyceraldehyde-3-phosphate dehydrogenase pro-
moter (GAPDHS), indicating specific binding in the ChIP
assays.
Promoter activities of CK2a and CK2b decrease
after inhibition of CK2 kinase activity
After exclusion of a direct binding of CK2 subunits to their
respective promoter regions, we next asked whether the
CK2 kinase activity might have an influence on the tran-
scriptional regulation of CK2a and/or CK2b. To address
this question, we transfected HCT116 cells with CK2a and
CK2b promoter constructs, subsequently, we blocked
endogenous CK2 kinase activity through treatment of the
cells with CX-4945, a highly selective inhibitor of CK2
kinase activity. It was shown earlier that sensitivity of
cancer cell lines to CX-4945 can vary in a broad range
[43]. Therefore, in early experiments we treated HCT116
cells with CX-4945 at different concentrations. Only about
65 % of endogenous CK2 kinase activity of HCT116 cells
was blocked after treatment with 1 lM of CX-4945, while
treatment of these cells with 10 lM of CX-4945 lead to a
nearly complete inhibition of endogenous CK2 kinase
activity (Fig. 5b). We therefore decided to use this CK2
inhibitor at a concentration of 10 lM for inhibition of
endogenous CK2 kinase activity. As shown in Fig. 5 about
90 % of endogenous CK2 kinase activity was inhibited
after treatment of the HCT116 cells with CX-4945 for 24 h
(Fig. 5b). Furthermore, promoter activities of both CK2a
and CK2b promoters were repressed in a dose-dependent
manner when endogenous CK2 kinase activity was blocked
by the selective CK2 inhibitor CX-4945 (Fig. 5a).
We further treated HCT116 cells with the structurally
unrelated CK2 inhibitor TF [34]. At a concentration of
50 lM TF, we found a decrease in endogenous CK2 kinase
activity (Fig. 5e) comparable to the effect of treatment of
the cells with 1 lM CX-4945 (Fig. 5b). Analyses of CK2
promoter activities (Fig. 5d) and endogenous CK2 mRNA
levels after treatment of the cells with TF (Fig. 5f),
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Fig. 3 Ectopic expression of non-catalytic subunit of CK2 did not
significantly change promoter activities of CK2a and CK2b promot-
ers. Dual luciferase reporter gene assays were carried out in HCT116
cells after transient cotransfection of wild-type CK2b alone (a), CK2a
together with CK2b (b), or CK2a0 together with CK2b (c) expression
plasmids together with indicated CK2 promoter constructs. The empty
expression plasmid p3xFLAG-CMV-7.1 served as vector control in
each case. Relative promoter activities measured 24, 48, and 72 h
(a) or only 24 h (b, c) after transient transfection, are shown. CK2
promoter activities measured after cotransfection with the vector
control were set to 100 %. Means and standard deviations of three
independent experiments are shown. *p \ 0.05, **p \ 0.01,
***p \ 0.001. Western blot analyses of cotransfected HCT116 cells
were analyzed in parallel and illustrate clear overexpression of
FLAG-tagged wild-type CK2b (a). Anti-FLAG antibody was used at
a dilution of 1:1,000. Detection of a-tubulin protein by anti-a-tubulin
antibody, at a dilution of 1:1,000, was used as a loading control for
the extracts in the experiments
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revealed similar effects as they are induced by 1 lM
CX-4945 (Fig. 5a, c).
Taken together, our data suggest, that CK2a and CK2a0
influence the expression of CK2a and CK2b, on the
transcriptional level not directly by binding to DNA but by
the CK2 kinase activity.
Discussion
The regulation of protein kinase CK2 has been the subject
of intensive research [44, 45]. Previous work mainly
focused on regulation of CK2 kinase activity and protein
level and led to the conviction, that CK2 is a ubiquitously
expressed, constitutively active kinase [46, 47]. However,
the CK2 kinase has also been shown to be a crucial con-
stituent of tightly regulated cellular processes [48–50]. In
addition, the expression and/or the activity of individual
CK2 subunits seem to be controlled independently but very
precisely. This is evidenced inter alia by differences in the
relative expression of individual CK2 transcripts during
embryonic development as well as by differential expres-
sion of CK2 genes in diverse tissues of adult animals [48,
51, 52]. For example, CK2a is widely expressed in all
human tissues while CK2a0 is predominantly expressed in
testis and in brain [10, 53]. Furthermore, the expression of
CK2b protein differs from that of CK2a and CK2a0 pro-
teins, suggesting variations in the composition of the tet-
rameric CK2 holoenzyme in different tissues [54]. The
underlying mechanisms for such differences may comprise
transcriptional and translational regulation, posttransla-
tional modifications, and stabilization of CK2 subunits at
both mRNA and protein level, as well as the subcellular
localization of individual CK2 subunits or CK2
holoenzyme.
Little is known to date about the transcriptional regu-
lation of CK2 subunit expression. In an early report, it was
shown that CK2 bound to calf thymus DNA and to k-phage
DNA [40]. Blotting experiments showed that DNA bound
CK2 through its a-subunits. Pyerin et al. [29, 41, 42, 55]
characterized DNA sequences upstream of the transcrip-
tional start sites as promoter regions and used different
fragments for promoter studies. Using gel mobility shift-
assays as well as DNaseI footprinting, CK2a was found to
bind to fragments within these promoter sequences but
only when CK2a was expressed in excess of CK2b [29].
To address this issue, we decided to analyze transcrip-
tional regulation of individual CK2 subunits with the focus
on potential self-regulatory mechanisms. Previous studies
suggested that relevant promoter regions of CK2a, CK2b
genes are located within a few hundred base pairs upstream
of the transcription start sites. In most of the experiments,
even smaller DNA fragments were used for the analysis of
transcriptional control [18, 56]. Interestingly, the CK2a
gene is organized with the first exon located over 35 kb
upstream of the second exon, which harbors the start
codon. Several eukaryotic genes are known with a first
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Fig. 4 Neither CK2a nor CK2b subunits are able to bind in vivo to
CK2a or CK2b promoter regions. Nuclear extracts were prepared and
chromatin immunoprecipitation analysis of CK2 subunit binding to
the human CK2a (a) or CK2b promoter (b) in vivo was performed
with antibodies targeting CK2a or CK2b. Primer positions are shown
in Fig. 1a, b. As negative controls, either no antibody (w/o antibody)
or a non-targeting rabbit antibody (IgG) was used. Analysis of SP1-
binding served as a positive control. All signals are given relative to
the input. c The GAPDHS promoter served as negative control for
SP1 binding
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large intron, which harbor regulatory elements influencing
gene expression [57–59]. Furthermore, it is described, that
most regulatory elements are located in the 50-flanking
region of the ATG start codon of genes [60, 61]. We
therefore were wondered, if there were essential regulatory
elements located directly upstream of the ATG start codon
of human CK2a gene, which may contribute to expression
control of CK2a subunit. In order to gain further insights
into the transcriptional regulation of the CK2a gene, we
cloned a potential promoter region proximate to the CK2a
start codon, encompassing over 1.3 kb (Fig. 1a, PI). We
however found, that this proximal promoter region does not
harbor any promoter activity (Fig. 1c). In contrast, analysis
of a distal promoter construct, containing 1.9 kb upstream
of the CK2a transcriptional start site (Fig. 1a, PII), reveals
a very strong promoter activity (Fig. 1c). We therefore
used this distal CK2a promoter construct for subsequent
investigations of CK2a transcriptional regulation.
The organization of the CK2b gene resemble that of
CK2a concerning location of the start codon within exon 2
(Fig. 1b). The first untranslated exon however, is separated
by a smaller intron, encompassing only 612 bp. In order to
include all potential regulatory sequences, we cloned a
DNA fragment of 1.9 kb upstream of the start codon of the
CK2b gene. This fragment includes complete sequences of
intron 1 and untranslated exon 1 as well as the 50-flanking
region upstream of CK2b transcriptional start site. Both,
the 1.3 kb upstream sequence of the CK2a gene and the
1.9 kb upstream sequence of the CK2b gene showed a
dose-dependent promoter activity.
We found that the catalytic subunits of CK2 led to a
moderate but significant trans-activation of both CK2a and
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Fig. 5 CK2 promoter activities and endogenous mRNA levels
decrease after inhibition of CK2 kinase activity with selective CK2
inhibitors CX-4945 (a–c) and TF (d–f). a, d Dual luciferase reporter
gene assays were carried out in HCT116 cells after transient
transfection of indicated CK2 promoter constructs for 24 h and
subsequent treatment with indicated concentrations of the CK2
inhibitors CX-4945 (a) or TF (d). Relative promoter activities,
measured 24 h after treatment of the cells, are presented. CK2
promoter activities measured in DMSO-treated cells were set to
100 %. b, e Endogenous CK2 kinase activity in HCT116 cells was
determined 24 h after treatment with DMSO (control) or indicated
concentrations of CK2 inhibitors CX-4945 (b) or TF (e). Relative
CK2 kinase activities measured in DMSO-treated control cells were
set to 100 %. c, f Endogenous mRNA levels of CK2a and CK2b were
determined after treatment of HCT116 cells with indicated concen-
trations of CK2 inhibitors CX-4945 (c) or TF (f). mRNA levels in
DMSO-treated control cells were set to 100 %
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CK2b promoters, whereas the b-subunit did not show any
significant transcriptional activation (Figs. 2, 3). According
to our data from ChIP analyses, neither CK2a nor CK2b
bound to promoter sequences (Fig. 4) which seems to be
different from the previous reports. However, Robitzki
et al. [29] only observed binding of CK2a to a promoter
element when CK2a was present in excess of CK2b. In
ChIP assays, we precipitated only endogenous CK2 sub-
units without any forced overexpression. Under these
conditions CK2a is complexed completely to CK2b. Thus,
we conclude from our results that CK2a and CK2b do not
function as transcription factors for their own expression.
This conclusion was supported by the observation that
inhibition of the kinase activity by two structurally unre-
lated inhibitors led to an attenuation of the transcriptional
activation of the CK2a and CK2b genes and to a decrease
in CK2 mRNA levels (Fig. 5). Probably due to the well-
known high protein stability of CK2 subunits ([15, 62] and
our own observation), we were not able to detect this effect
on protein level (data not shown). Remarkable, inhibition
of over 90 % of endogenous CK2 kinase activity by
CX-4945 (Fig. 5b) only leads to downregulation of pro-
moter activities of about 50 % (CK2a) or 25 % (CK2b),
respectively (Fig. 5a). This discrepancy may be explained
by basal control mechanisms of CK2 promoter activities.
CK2a as well as CK2b promoters were basically influenced
by several transcription factors, including SP1, ETS1, and
NFjB [50, 51, 57]. Obviously, these transcription factors
generate basal promoter activities of both promoters, while
CK2 kinase activity itself seems to be responsible for the
respective fine regulation and required for full promoter
activities.
Therefore, our data suggest that CK2 regulates its
transcription by phosphorylation of transcription factors.
One of the candidates may be SP1 which was shown in this
study to bind to both promoter elements and which was
shown to be a substrate for CK2 [63, 64]. However, it was
shown that phosphorylation of SP1 by CK2 led to a
decrease in the DNA-binding activity of SP1 [63]. Thus,
we conclude that SP1 is not the transcription factor which
is activated by CK2 for the regulation of the CK2 gene
expression. Ets1 is another transcription factor which is
supposed to bind to the CK2a promoter [56]. So far, it is
not known whether Ets1 is a substrate for CK2. However,
there may be a number of other transcription factors
implicated in the regulation of CK2 gene expression which
are not known so far. Work to identify these factors is
currently in progress.
We have shown here that under normal physiological
conditions CK2 does not bind to CK2 promoter regions and
that the CK2 kinase activity is implicated in the regulation
of CK2a and CK2b gene expressions.
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